Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s159690
Abstract: In the last 15 years relevant efforts have been made to demonstrate that calcitonin gene-related peptide (CGRP) antagonism is a valuable and druggable mechanism for treatment or prevention of migraine. Galcanezumab is one of the… read more here.
Keywords: prevention migraine; monthly galcanezumab; migraine adults; migraine ... See more keywords